🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,760 results for “Pharm” Clear

  1. Telotristat etiprate

    LEXICON PHARMACEUTICALS, INC.

    Carcinoid Syndrome

    phase 3 small molecule completed

    5 trials

  2. Temodal 100 mg hard capsules, Temodal 250 mg hard capsules, Placebo, 2-Hydroxyoleic acid sodium salt, Temodal 140 mg hard capsules, Temodal 5 mg hard capsules, Temodal 20 mg hard capsules, Temodal 180 mg hard capsules

    Lacuna Pharma Pty Ltd

    Newly diagnosed primary glioblastoma multiforme (ndGBM)

    phase 3 small molecule active

    1 trial

  3. Temomedac 20 mg hard capsules, Temomedac 5 mg hard capsules, Tirabrutinib, Temomedac 100 mg hard capsules, Truxima 500 mg concentrate for solution for infusion, Truxima 100 mg concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Relapsed/refractory primary central nervous system lymphoma

    phase 3 small molecule active

    1 trial

  4. Temozolomide

    GT Biopharma

    Glioblastoma

    phase 3 small molecule active

    1 trial

  5. Test - Bimatoprost 0.01% Ophthalmic Solution

    Amneal Pharma Europe Ltd

    Glaucoma, Open-Angle

    phase 3 small molecule active

    1 trial

  6. Test Product

    Amneal Pharma Europe Ltd

    Asthma

    phase 3 small molecule active

    2 trials

  7. Testosterone Topical Gel, 1.62% Metered Pump

    Amneal Pharma Europe Ltd

    Primary Hypogonadism

    phase 3 small molecule completed

    1 trial

  8. Tetrahydrocannabinol

    Jazz Pharmaceuticals Ireland Limited

    Pain, Postoperative

    phase 3 small molecule active

    1 trial

  9. Tezacaftor/Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    3 trials

  10. The placebo for NW-3509 drug product contains blended lactose monohydrate (29.50 mg/caps), microcrystalline cellulose (70.00 mg/caps), and magnesium stearate (0.50 mg/caps) filled into hard gelatin capsules.

    Lacuna Pharma Pty Ltd

    treatment-resistant schizophrenia (TRS)

    phase 3 small molecule active

    1 trial

  11. The placebo has the same composition as the investigational medicinal product Clinitrat® (6.563+175,4+89,3+23,3) mg/sachet (with the exception of the active substance), is manufactured by the same manufacturer (uni-pharma kleon tsetis pharmaceutical laboratory s.a) and is not sterile., CLINITRAT® (6.563+175,4+89,3+23,3) mg/sachet ή stick, Κόνις για πόσιμο διάλυμα

    Lacuna Pharma Pty Ltd

    Second line treatment for colonoscopy preparation

    phase 3 small molecule active

    1 trial

  12. The placebo product is manufactured to visually match the corresponding FDY-5301 injection drug product. It is formulated to match a standard saline solution comprised of Sodium Chloride and Water for Injection.

    Lacuna Pharma Pty Ltd

    Anterior ST-Elevation Myocardial Infarction

    phase 3 small molecule active

    1 trial

  13. Ticagrelor 90 mg

    COLLEGIUM PHARMACEUTICAL, INC

    Myocardial Infarction

    phase 3 small molecule completed

    1 trial

  14. Ticagrelor 90mg

    COLLEGIUM PHARMACEUTICAL, INC

    STEMI

    phase 3 small molecule active

    1 trial

  15. Tildrakizumab Placebo Solution for Injection, TILDRAKIZUMAB

    Lacuna Pharma Pty Ltd

    Moderate to Severe Genital Psoriasis

    phase 3 small molecule active

    1 trial

  16. Tildrakizumab matching placebo, Enbrel 25 mg powder for solution for injection, Tildrakizumab

    Lacuna Pharma Pty Ltd

    Treatment of pediatric subjects with moderate to severe chronic plaque psoriasis

    phase 3 small molecule active

    1 trial

  17. Tinlarebant 5 mg´s matching Placebo, LBS-008

    ELITE PHARMACEUTICALS INC /NV/

    Stargardt Disease

    phase 3 small molecule active

    1 trial

  18. Tofersen

    IONIS PHARMACEUTICALS INC

    ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

    phase 3 small molecule completed

    1 trial

  19. Tofersen

    IONIS PHARMACEUTICALS INC

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule completed

    1 trial

  20. Topotecan HEXAL 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Anastrozol STADA® 1 mg Filmtabletten, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, VS-6766, LETRO-cell® 2,5 mg Filmtabletten, VS-6063, Letrozol - 1 A Pharma® 2,5 mg Filmtabletten, ZOLSKETIL pegylated liposomal 2 mg/mL concentrate for dispersion for inf

    Vera Therapeutics

    Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

    phase 3 small molecule active

    1 trial

  21. Tovorafenib, VINCRISIN 1 mg/ml solution injectable, 2 mg, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Tovorafenib, VELBE 10 mg Trockensubstanz zur Injektionsbereitung, Vinblastin STADA 10 mg Pulver zur Herstellung einer Injektionslösung, cellcristin® 1 mg/ml Injektionslösung Wirkstoff: Vincristinsulfat, Vincristinesulfaat Teva 1 mg/ml, oplossing voor injectie, Vinblastinesulfaat 1 mg/ml PCH, oplossing voor injectie

    Lacuna Pharma Pty Ltd

    Pediatric low-grade glioma harboring an activating RAF alteration requiring first-line systemic therapy

    phase 3 small molecule active

    1 trial

  22. Trabectedin

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Ovarian Cancer

    phase 3 small molecule completed

    1 trial

  23. Trabectedin EVER Pharma 1 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Pazopanib PharOS 200 mg film-coated tablets, HALAVEN 0.44 mg/ml solution for injection

    INTENSITY THERAPEUTICS, INC.

    liposarcoma (dedifferentiated, myxoid, round cell or pleomorphic), Leiomyosarcoma (non-uterine), Undifferentiated pleomorphic sarcoma

    phase 3 small molecule active

    1 trial

  24. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Idiopathic Gastroparesis

    phase 3 small molecule active

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources